

## Web Appendix A. Study Characteristics

Author (year)	Continent	Country	Special Population	Randomization	Intervention Description	N
Mazumder (2014)	Asia	India	None	Individually randomized	Trial comparing NVAS (50,000 IU) to placebo within 3 days after birth	44,984
Rahmathullah (2003)	Asia	South India	None	Individually randomized	Trial comparing NVAS (48,000 IU) to placebo within 3 days after birth	13,294
Klemm (2008)	Asia	Bangladesh	None	Cluster randomized	Trial comparing NVAS (50,000 IU) to placebo within 30 days after birth (nested within MVAS trial)	15,902
Humphrey (1996)	Asia	Indonesia	None	Individually randomized (within birthweight strata)	Trial comparing NVAS (52 umol) to placebo within 1 day after birth	2,067
Edmond (2014)	Africa	Ghana	None	Individually randomized	Trial comparing NVAS (50,000 IU) to placebo within 3 days after birth	22,955
Masanja (2014)	Africa	Tanzania	None	Individually randomized	Trial comparing NVAS (50,000 IU) to placebo within 3 days after birth	31,999
Benn (2008)	Africa	Guinea Bissau	Normal birthweight infants	Individually randomized	Trial comparing NVAS (50,000 IU) to placebo	4,345
Benn (2010)	Africa	Guinea Bissau	Low birthweight infants	Individually randomized	Trial comparing NVAS (25,000 IU) to placebo (plus early BCG vaccine or the usual delayed BCG vaccine)	1,736
Benn (2014)	Africa	Guinea Bissau	Normal birthweight infants	Individually randomized	Trial comparing NVAS (50,000 IU) to NVAS (25,000 IU) to placebo	6,048
Malaba (2005) & Humprey (2006)	Africa	Zimbabwe	None	Individually randomized	Trial comparing NVAS (50,000IU); MVAS (400,000 IU); NVAS+MVAS; or placebo	14,104
Soofi (2016)	Asia	Pakistan	None	Cluster randomized	Trial comparing NVAS (50,000 IU) to placebo within 3 days after birth	11,028